Scarica l'app Stockscreener
82.08
1.99%
1.60
Dopo l'orario di chiusura:
79.50
-2.58
-3.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NUVL Giù?
Forum
Previsione
Precedente Chiudi:
$80.48
Aprire:
$80.14
Volume 24 ore:
326.74K
Relative Volume:
0.63
Capitalizzazione di mercato:
$5.45B
Reddito:
-
Utile/perdita netta:
$-224.29M
Rapporto P/E:
-21.05
EPS:
-3.9
Flusso di cassa netto:
$-185.06M
1 W Prestazione:
-4.21%
1M Prestazione:
+6.76%
6M Prestazione:
-0.18%
1 anno Prestazione:
+2.22%
Intervallo 1D:
$80.14
$82.54
Intervallo di 1 settimana:
$80.14
$86.49
Portata 52W:
$55.53
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Nome
Nuvalent Inc
Settore
Industria
Telefono
508-446-2272
Indirizzo
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Confronta NUVL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
82.08 | 5.78B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-14 | Aggiornamento | UBS | Neutral → Buy |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-24 | Iniziato | UBS | Neutral |
| 2024-08-29 | Iniziato | Barclays | Overweight |
| 2024-04-17 | Iniziato | Jefferies | Buy |
| 2024-04-01 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Ripresa | Guggenheim | Buy |
| 2024-02-23 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-27 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-24 | Iniziato | Guggenheim | Buy |
| 2023-01-18 | Iniziato | Wedbush | Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
Mostra tutto
Nuvalent Inc Borsa (NUVL) Ultime notizie
What institutions are buying Nuvalent Inc. stock nowSky-high return potential - jammulinksnews.com
Is Nuvalent Inc. a good long term investmentPowerful profit generation - PrintWeekIndia
Nuvalent Inc. Stock Analysis and ForecastHigh-yield capital appreciation - Autocar Professional
What drives Nuvalent Inc. stock priceConsistent triple returns - Autocar Professional
What analysts say about Nuvalent Inc. stockExplosive earnings growth - jammulinksnews.com
Nuvalent Initiates Phase 3 ALKAZAR Trial of Neladalkib in NSCLC - Pharmacy Times
Nuvalent begins Phase 3 trial of neladalkib in ALK-positive lung cancer - Investing.com
Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial - TipRanks
Nuvalent doses first patient in phase 3 lung cancer drug trial - Investing.com Nigeria
Nuvalent announces initiation of Alkazar phase 3 randomized - MarketScreener
Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC - PR Newswire
How high can Nuvalent Inc. stock price go in 2025Profitable Yet Secure Picks - Newser
Nuvalent(NUVL) Shares Soar 3.01% on Positive Clinical Data - AInvest
Nuvalent, Inc. (NASDAQ:NUVL) Stock Position Decreased by Teacher Retirement System of Texas - Defense World
Why Nuvalent Inc. stock attracts strong analyst attentionDaily Trade Opportunity - Newser
How Nuvalent Inc. stock performs during market volatilityFree Capital Allocation Plans - Newser
What makes Nuvalent Inc. stock price move sharplyFree Access to Stock Community - Newser
Recent Analysts’ Ratings Updates for Nuvalent (NUVL) - Defense World
Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells $439,890.00 in Stock - Defense World
Nuvalent's Insider Sales and Clinical Milestones: A Balancing Act for Investors - AInvest
Nuvalent(NUVL) Shares Soar 3.47% on Positive Lung Cancer Data - AInvest
Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer - MSN
Nuvalent’s SWOT analysis: biotech stock’s pivotal year ahead By Investing.com - Investing.com Nigeria
Nuvalent’s SWOT analysis: biotech stock’s pivotal year ahead - Investing.com
Nuvalent Inc Azioni (NUVL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):